{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/corticosteroids-topical-skin-nose-eyes/background-information/availability/","result":{"pageContext":{"chapter":{"id":"8e053a89-aa32-5f75-aefc-61b421905b9d","slug":"availability","fullItemName":"Availability","depth":2,"htmlHeader":"<!-- begin field 47d93546-07ac-43ce-b6a5-5dd52f46f9a1 --><h2>Which local (skin, nose and eyes) corticosteroids are available in the UK?</h2><!-- end field 47d93546-07ac-43ce-b6a5-5dd52f46f9a1 -->","summary":"","htmlStringContent":"<!-- begin item 7500fc54-dfdf-4980-b381-b6752cce2a5a --><!-- end item 7500fc54-dfdf-4980-b381-b6752cce2a5a -->","topic":{"id":"091d926b-472d-55aa-b732-215f8299eb6e","topicId":"fe2967bf-dc0e-4dd2-903c-812a35c0d510","topicName":"Corticosteroids - topical (skin), nose, and eyes","slug":"corticosteroids-topical-skin-nose-eyes","lastRevised":"Last revised in September 2020","chapters":[{"id":"d7e6a05a-1ad6-5002-9e1d-418bb0509a7e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"30c29984-be54-5cc7-b45b-ccea8330c500","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"01ed2c05-1414-51dd-85da-6ddc4bbc005d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"791cb5ff-e017-51d6-b7ee-cabacb293b82","slug":"changes","fullItemName":"Changes"},{"id":"110d5d5e-8e14-51d5-ab15-5afa0d551cf7","slug":"update","fullItemName":"Update"}]},{"id":"6481ae53-8731-5bbf-84bb-f9c18452558f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"746ed409-c3cc-5d5f-a043-6c7e517b0f61","slug":"goals","fullItemName":"Goals"},{"id":"40ab5ace-33b8-5a2c-a6bb-cbd7fe8ca07c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc1a105d-dd83-5e54-b930-588a3dbdb5cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f6a0228b-0765-5b1b-b1b7-25eca749a1ab","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"842d280b-d84c-5903-bbdb-3f4fe26412fc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"17589721-7493-5da3-8828-e2b4bec649b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e1a50e32-af60-5677-ad61-93b4be058bdd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e28586d8-7d65-5f08-a10b-d2d25b975112","slug":"definition","fullItemName":"Definition"},{"id":"58a9256e-a859-56a0-a7a3-946a224e6310","slug":"action-of-local-corticosteroids","fullItemName":"Action of local corticosteroids"},{"id":"8e053a89-aa32-5f75-aefc-61b421905b9d","slug":"availability","fullItemName":"Availability"}]},{"id":"1967c89c-d7ce-51d0-a539-3bf6738b65b4","fullItemName":"Management","slug":"management","subChapters":[{"id":"b60ad525-96a0-5836-9db8-d24fc5c18423","slug":"topical-treatment","fullItemName":"Scenario: Topical treatment"},{"id":"520275be-3f1d-5e10-8de2-5524f170f2ba","slug":"intranasal-corticosteroid-treatment","fullItemName":"Scenario: Intranasal corticosteroid treatment"},{"id":"f718a357-8e9a-50d8-ad33-87c1b4345715","slug":"eye-treatment","fullItemName":"Scenario: Eye treatment"}]},{"id":"ebd50a03-95ac-50a9-8a2d-4d615c9569bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0620ec75-3526-5198-b134-4f31d225ab30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2b03e883-8770-59d5-9965-04ffada0e471","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73e06218-1739-5de2-908f-ba65ba970168","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f813f700-2fb0-5989-90bd-2c2aa6dbb85a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3aa0e05-0446-53c0-9de1-2a8d2a9d1a70","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2a6ead30-5d09-5a96-b6d4-b673b755b98a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e78ffc84-8544-5685-8a35-65c8f05aac92","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e1a50e32-af60-5677-ad61-93b4be058bdd","slug":"background-information","fullItemName":"Background information"},"subChapters":[{"id":"bf0593c6-88f5-5bd8-8050-42072b1957d0","slug":"topical","fullItemName":"Topical","depth":3,"htmlHeader":"<!-- begin field 2ad4e400-7ae0-4510-917c-a74a009d4860 --><h3>Topical</h3><!-- end field 2ad4e400-7ae0-4510-917c-a74a009d4860 -->","summary":null,"htmlStringContent":"<!-- begin item a55786cc-920c-41bb-acb0-a74a009d46f3 --><!-- begin field 2ea35edb-f3f1-4fbb-917d-a74a009d4860 --><ul><li>Topical corticosteroids are available in different <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#formulations\">Formulations</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#potency\">Potency</a>. Some are also available as compound preparations containing substances such as antibacterials, antifungals, or salicylic acid. <ul><li>The benefit of combining antibacterials or antifungals with a topical corticosteroid is uncertain. </li><li>When prescribing combination products, select the antimicrobial drug according to the sensitivity of the infecting organism. The preparation should typically be used twice daily for a maximum of 7 days. Longer use increases the risk of resistance and sensitization. </li></ul></li><li>Small packs of hydrocortisone (alone or combined with other ingredients) and clobetasone butyrate (15 g tube) are licenced to be purchased over-the-counter for use by adults and children aged over 10 years and 12 years, respectively, for short term use (maximum 7 days) in skin conditions such as eczema.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>] </p><!-- end field 2ea35edb-f3f1-4fbb-917d-a74a009d4860 --><!-- end item a55786cc-920c-41bb-acb0-a74a009d46f3 -->","subChapters":[]},{"id":"83826be4-dfc4-539f-8d0e-f389bbede801","slug":"intranasal","fullItemName":"Intranasal","depth":3,"htmlHeader":"<!-- begin field 9e0593e8-aef3-4c85-856a-a74a009e37a3 --><h3>Intranasal</h3><!-- end field 9e0593e8-aef3-4c85-856a-a74a009e37a3 -->","summary":null,"htmlStringContent":"<!-- begin item 16ea613c-0312-462b-8638-a74a009e3767 --><!-- begin field e7766f04-e097-4c04-a389-a74a009e37a3 --><ul><li>The intranasal corticosteroids that are available in the UK include:<ul><li>Beclometasone dipropionate (spray).</li><li>Betamethasone sodium phosphate (drops).</li><li>Budesonide (spray).</li><li>Fluticasone propionate aqueous (spray and drops).</li><li>Mometasone furoate (spray).</li><li>Triamcinolone acetonide (aqueous spray).</li></ul></li><li>Small packs of some intranasal corticosteroids (beclometasone, fluticasone, and triamcinolone) are available over-the-counter for the prevention and treatment of seasonal allergic rhinitis in adults aged 18 years and over.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2020b</a>]</p><!-- end field e7766f04-e097-4c04-a389-a74a009e37a3 --><!-- end item 16ea613c-0312-462b-8638-a74a009e3767 -->","subChapters":[]},{"id":"5213ad2e-097d-57e2-b7e2-29e8f4eea378","slug":"eye-preparations","fullItemName":"Eye preparations","depth":3,"htmlHeader":"<!-- begin field 2e21709a-4dc8-4b91-9bf3-a74a009ec153 --><h3>Eye preparations</h3><!-- end field 2e21709a-4dc8-4b91-9bf3-a74a009ec153 -->","summary":null,"htmlStringContent":"<!-- begin item 13ed927c-e1b4-499f-916e-a74a009ec0b7 --><!-- begin field 49c96a2e-90cf-4a8b-beb8-a74a009ec153 --><ul><li>Corticosteroid eye preparations are available as drops, ointments, ophthalmic suspensions, and preservative-free, unit dose drops. Some are also available as compound preparations containing antibacterials.</li><li>The corticosteroid eye preparations available in the UK include:<ul><li>Betamethasone (drops and ointment).</li><li>Dexamethasone (drops and unit dose drops).</li><li>Fluorometholone (ophthalmic suspension).</li><li>Hydrocortisone acetate (drops and ointment).</li><li>Loteprednol etabonate (ophthalmic suspension).</li><li>Prednisolone (drops and unit dose drops).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 49c96a2e-90cf-4a8b-beb8-a74a009ec153 --><!-- end item 13ed927c-e1b4-499f-916e-a74a009ec0b7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}